Evonik to invest 93 million euros in Vancouver lipid-based drug production

Evonik is investing over 150 million Canadian dollars (approximately 93 million euros) to expand its development and production capacities for lipid-based drug delivery at its site in Vancouver, Canada. The project includes the construction of a new Good Manufacturing Practice (GMP) facility designed to support pharmaceutical and biotech companies in developing lipid-based medicines, such as vaccines and therapeutics, through to commercial production.

The Canadian government’s Strategic Response Fund is supporting the project with up to 68 million Canadian dollars (42 million euros). The new facility is expected to triple Evonik’s current production capacities for advanced pharmaceutical products and enhance quality assurance and microbiological testing capabilities, allowing for faster product release for clinical trials. Drug production at the site is scheduled to begin by the end of 2029.